{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-065603","form_type":"8-K","ticker":"INAB","cik":"0001740279","company_name":"IN8BIO, INC.","filed_at":"2025-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.530520+00:00","generated_at":"2026-05-22T08:34:47.684551+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"IN8bio reports Q1 2025 net loss of $5.6M; INB-100 shows 100% AML relapse-free at 20.1 months","bullets":["Net loss $5.6M ($0.07/sh) vs. $8.6M ($0.20/sh) prior year; cash $11.9M as of March 31, 2025.","Phase 1 INB-100 data: 100% AML patients relapse-free at median 20.1 months follow-up; no CRS/ICANs.","Presented INB-600 TCE platform at AACR 2025 showing picomolar potency and minimal cytokine release.","Upcoming oral presentation at ASCO 2025 for INB-200 in glioblastoma (May 30, 2025).","Raised ~$4.1M net from ATM and warrant exercises in Q1 2025; additional $1.9M gross in April 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-065603","json":"https://secwatch.observer/filing/0000950170-25-065603.json","markdown":"https://secwatch.observer/filing/0000950170-25-065603.md","text":"https://secwatch.observer/filing/0000950170-25-065603.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1740279/000095017025065603/0000950170-25-065603-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1740279/000095017025065603/inab-20250507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T08:34:47.684551+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}